Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis.
Neutrophils are not homogeneous, however, and could play different roles in cancer …

Despite improved methods of diagnosis and the development of different treatments,
mortality from lung cancer remains surprisingly high. Non-small cell lung cancer (NSCLC) …

Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly
poor prognosis. For decades, the best available systemic therapy was platinum plus …

Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a
particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage …

For many years the standard of care for small cell lung cancer (SCLC) has remained
unchanged. Despite decades of active research, current treatment options are limited and …

Background The current standard treatment for limited-stage small-cell lung cancer (LS-
SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT). Methods In this single …

​ Background Immunotherapy for lung cancer has been a hot research area for years. This
bibliometric analysis aims to present the research trends on lung cancer immunotherapy …

Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately
15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical …